Lexicon Pharmaceuticals/$LXRX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Ticker
$LXRX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
103
ISIN
US5288723027
Website
LXRX Metrics
BasicAdvanced
$333M
-
-$0.51
1.08
-
Price and volume
Market cap
$333M
Beta
1.08
52-week high
$2.45
52-week low
$0.28
Average daily volume
4.7M
Financial strength
Current ratio
2.783
Quick ratio
2.189
Long term debt to equity
51.339
Total debt to equity
86.37
Interest coverage (TTM)
-13.25%
Profitability
EBITDA (TTM)
-164.64
Gross margin (TTM)
-172.09%
Net profit margin (TTM)
-568.04%
Operating margin (TTM)
-529.15%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
-28.88%
Return on equity (TTM)
-86.09%
Valuation
Price to revenue (TTM)
10.247
Price to book
2.7
Price to tangible book (TTM)
4.23
Price to free cash flow (TTM)
-1.899
Free cash flow yield (TTM)
-52.67%
Free cash flow per share (TTM)
-48.24%
Growth
Revenue change (TTM)
1,251.21%
Earnings per share change (TTM)
-38.30%
3-year revenue growth (CAGR)
366.22%
10-year revenue growth (CAGR)
2.51%
3-year earnings per share growth (CAGR)
-6.12%
10-year earnings per share growth (CAGR)
-7.95%
What the Analysts think about LXRX
Analyst ratings (Buy, Hold, Sell) for Lexicon Pharmaceuticals stock.
Bulls say / Bears say
Lexicon Pharmaceuticals secured a licensing agreement with Novo Nordisk for its experimental obesity drug LX9851, potentially worth up to $1 billion, indicating strong confidence in the drug's market potential. (reuters.com)
The FDA approved Lexicon's heart failure drug, Inpefa, positioning the company to enter a competitive market with significant revenue potential. (nasdaq.com)
Institutional investors, including FMR LLC and Point72 Asset Management, have significantly increased their holdings in Lexicon, reflecting confidence in the company's future prospects. (defenseworld.net)
Lexicon's recent $125 million stock offering led to a nearly 15% decline in share price, raising concerns about potential dilution and financial stability. (nasdaq.com)
Analysts have issued cautious ratings, with StockNews.com initiating coverage with a 'sell' rating and Piper Sandler lowering the price target from $10.00 to $6.00, indicating skepticism about the company's near-term performance. (marketbeat.com)
The departure of President and COO Jeff Wade after 25 years raises concerns about potential disruptions in leadership and strategic direction. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 4 Jul 2025.
LXRX Financial Performance
Revenues and expenses
LXRX Earnings Performance
Company profitability
LXRX News
AllArticlesVideos
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
GlobeNewsWire·2 weeks ago
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
GlobeNewsWire·2 weeks ago
Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lexicon Pharmaceuticals stock?
Lexicon Pharmaceuticals (LXRX) has a market cap of $333M as of July 04, 2025.
What is the P/E ratio for Lexicon Pharmaceuticals stock?
The price to earnings (P/E) ratio for Lexicon Pharmaceuticals (LXRX) stock is 0 as of July 04, 2025.
Does Lexicon Pharmaceuticals stock pay dividends?
No, Lexicon Pharmaceuticals (LXRX) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Lexicon Pharmaceuticals dividend payment date?
Lexicon Pharmaceuticals (LXRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals (LXRX) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.